Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Dazucorilant · CORT-113176

Small molecule · developed by Corcept Therapeutics

Phase 2 Most advanced trial

CORT Developer

4 Registered trials

What is Dazucorilant?

Dazucorilant is an investigational small-molecule drug studied in Amyotrophic Lateral Sclerosis, Healthy Adults, Healthy.

At a glance

Also known as: CORT-113176, [14C]-CORT113176
Drug type: Small molecule
Therapy area: Neurology
Developer: Corcept Therapeutics (CORT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: HR4RD5RBJ6

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05407324	Phase 2	Amyotrophic Lateral Sclerosis	Active not recruiting	CORT
NCT04990310	Phase 1	Healthy	Completed	CORT
NCT04994743	Phase 1	Healthy Adults	Completed	CORT
NCT04249323	Phase 1	Healthy Adults	Completed	CORT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Amyotrophic Lateral SclerosisHealthyHealthy Adults

More from Corcept Therapeutics

Relacorilant FDA approved CORT125236 Phase 1 CORT125329 Phase 1 Exicorilant Phase 1/2 Miricorilant Phase 2 Nenocorilant Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the CORT page.

Follow CORT, the company behind Dazucorilant

See CORT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CORT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z